Market Place
Sourcing Support
Zevra Therapeutics Completes Acquisition of Acer Therapeutics
20 Nov 2023 //
GLOBENEWSWIRE
ISS Recommend Acer Therapeutics Shareholders Vote FOR" the Proposed Merger"
02 Nov 2023 //
GLOBENEWSWIRE
Acer Reacquires Worldwide Development, Commercialization Rights to OLPRUVA
30 Aug 2023 //
GLOBENEWSWIRE
Relief Announces New Exclusive Definitive Agreement for OLPRUVA(TM) (ACER-001)
30 Aug 2023 //
ACCESSWIRE
Acer Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Acer Receives $1M Capital Infusion from Chief Executive Officer and Founder
26 Jun 2023 //
GLOBENEWSWIRE
Acer Therapeutics Reports Q1 2023 Financial & Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
Acer Therapeutics Announces OLPRUVA Commercial Launch Progressing Ahead
01 May 2023 //
GLOBENEWSWIRE
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Acer Therapeutics Announces $2.675 Million Registered Direct Offering
22 Mar 2023 //
GLOBENEWSWIRE
Acer Announces Data Presented Identifying Preferred Urea Cycle Disorder Treatment Attributes
22 Mar 2023 //
GLOBENEWSWIRE
Cash-strapped Acer sees menopause drug flunk phase 2 trial
18 Mar 2023 //
FIERCE BIOTECH
Acer Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data
15 Mar 2023 //
GLOBENEWSWIRE
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801
13 Feb 2023 //
GLOBENEWSWIRE
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements
09 Jan 2023 //
GLOBENEWSWIRE
Acer Announces Initiation of Two Investigr-Sponsored Trials of ACER-801
05 Jan 2023 //
GLOBENEWSWIRE
Acer, Relief win FDA approval for rare disease after clearing inspection
28 Dec 2022 //
ENDPTS
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA
27 Dec 2022 //
GLOBENEWSWIRE
US FDA approves Acer Therapeutics` genetic disorder drug
24 Dec 2022 //
ECONOMICTIMES
Acer Therapeutics Announces $1.5M Private Placement
30 Nov 2022 //
GLOBENEWSWIRE
Acer Therapeutics Reports Q3 2022 Financial Results &Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Acer Receives Notice of Allowance of Key US Patent Application Covering EDSIVO
26 Oct 2022 //
GLOBENEWSWIRE
Acer Announces University of NC Receives Department of Defense Grant ACER-801
06 Oct 2022 //
GLOBENEWSWIRE
Acer Therapeutics Announces Expansion of ACER-801 (osanetant) DevP
05 Oct 2022 //
GLOBENEWSWIRE
Acer Therapeutics & Relief Therapeutics Announce Receipt of Notice of Allowance
03 Oct 2022 //
GLOBENEWSWIRE
Acer Therapeutics to Participate in August and September 2022 Conferences
23 Aug 2022 //
GLOBENEWSWIRE
Acer Therapeutics Reports Q2 2022 Financial Results & Provides Corporate Update
15 Aug 2022 //
GLOBENEWSWIRE
Relief Therapeutics & Acer Announce that the EU Has Granted ODD for ACER-001
12 Aug 2022 //
GLOBENEWSWIRE
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission
28 Jul 2022 //
GLOBENEWSWIRE
Acer Therapeutics Resubmits NDA For ACER-001 in Urea Cycle Disorders
19 Jul 2022 //
NASDAQ
Relief Tx Announces that its Collaboration Partner has Resubmitted ACER-001 NDA
18 Jul 2022 //
BIOSPACE
CNIPA Issue Patent 11,202,767 Covering ACER-001 Dosage Form to Acer and Relief
08 Jul 2022 //
GLOBENEWSWIRE
Acer Tx Initiates Pivotal PIII DiSCOVER Trial of EDSIVO for VED Syndrome
27 Jun 2022 //
GLOBENEWSWIRE
Acer fumbles at FDA, receiving CRL due to lack of inspection readiness
22 Jun 2022 //
ENDPTS
Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
21 Jun 2022 //
GLOBENEWSWIRE
Acer Tx Issues Statement Regarding PDUFA Target Action Date for ACER-001
07 Jun 2022 //
GLOBENEWSWIRE
New Improved Drug Expected to Get FDA Approval Next Mont
23 May 2022 //
INVESTORIDEAS
Acer Therapeutics Reports Q1 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment
09 May 2022 //
GLOBENEWSWIRE
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data
06 May 2022 //
GLOBENEWSWIRE
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
05 May 2022 //
GLOBENEWSWIRE
Acer and Relief to Present ACER-001 Data at SIMD 2022
12 Apr 2022 //
ACCESSWIRE
Acer and Relief Therapeutics Announce Presentation of ACER-001 Data at SIMD
12 Apr 2022 //
GLOBENEWSWIRE
Acer Therapeutics` EDSIVO Granted FDA BTD for Vascular Ehlers-Danlos Syndrome
04 Apr 2022 //
GLOBENEWSWIRE
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard
31 Mar 2022 //
GLOBENEWSWIRE
Acer Tx Enrolls First Patient in its Phase 2a Trial of ACER-801
30 Mar 2022 //
GLOBENEWSWIRE
Acer Tx Secures up to $48.5M in Convertible Note and Secured Loan Financing
07 Mar 2022 //
GLOBENEWSWIRE
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results
02 Mar 2022 //
GLOBENEWSWIRE
Acer was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use
01 Feb 2022 //
BIOSPACE
Relief Announces That Collaboration Partner, Acer , was Issued U.S. Patent
01 Feb 2022 //
ACCESSWIRE
Acer Tx, Relief Tx Presents Four ACER-001 Posters at SIMD and GMDI Conferences
27 Jan 2022 //
GLOBENEWSWIRE
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment
09 Dec 2021 //
GLOBENEWSWIRE
Acer Therapeutics Reports Q3 2021 Results and Provides Corporate Update
20 Nov 2021 //
GLOBENEWSWIRE
Acer Therapeutics and Relief Announce Issuance of U.S. Patent ACER-001
26 Oct 2021 //
GLOBENEWSWIRE
Acer & Relief Announce FDA Acceptance for Filing of NDA for ACER-001
06 Oct 2021 //
GLOBENEWSWIRE
ACER & RELIEF THERAPEUTICS SUBMIT NDA OF ACER-001TO FDA IN UREA CYCLE DISORDERS
30 Sep 2021 //
NEWSLETTER
Augmedix Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
GLOBENEWSWIRE
Augmedix Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
GLOBENEWSWIRE
Acer and Relief Announce Submission of a NDA to the U.S. FDA for ACER-001
09 Aug 2021 //
BIOSPACE
Acer Therapeutics Plans Clinical Trial for EDSIVO
10 Jun 2021 //
GLOBENEWSWIRE
